Hormone Receptor-Positive Breast Carcinoma

Hormone Receptor-Positive Breast Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

67 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 36
Recruiting: 25
Ph III recruiting: 3
Growth YoY: —
Industry share: 14%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (14)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06590558	Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer	withdrawn	Phase 1	0	National Cancer Institute (NCI)NIH	0	Jul 3, 2025	clinicaltrials
NCT04756505	Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial	withdrawn	Phase 1	0	M.D. Anderson Cancer CenterOTHER	0